ABCSG 39/Aphinity Summary
Randomized, multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo vs. chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
Link for studyteam-members only
Further information about this trial
Access to these informations only with keyword. If required, please ask the responsible project manager.